restoration
screeningBehavior
paper
thepresence
filipinoWomen
controlGroup
novelTargetedTherapeuticOptions
theirApplication
maintainedBreastCancerDatabase
reality
physicalActivity
periods
edition
type
theirSurvival
p<
yearRfsrate
depletion
supplements
Isolation
nonparticipation
breastConservation
95PercecntConfidenceIntervals
breastExamination
promisingSupplements
greaterthanorequalto10PercecntDecline
theResulting
textureFeatures
ovarianCancer
recurrence
specimen
deregulatedMirnas
microRNAs
twenty-twoPatients
aberrantDnaMethylation
statisticalAssociation
frequentCancer
histology
premenopausalPatients
dysregulation
sox9NucleusEntry
methylation
tumorSize
ctnLevels
Demographics
neutrophil-to-lymphocyteRatio
aspirationCytology
handicap
assessment
BRCA1/2
severalIntelligentTechniques
essentialRole
knowledgeSummaries
subgroupVariables
advancedAnalysis
symptoms
ourFindings
previousCervicalCancerScreening
tumorCells
Analysis
status
female
SNPs
vulnerability
theirAbility
betterUnderstanding
complexTreatmentAlgorithms
flowRate
them
differentialDiagnosis
comparisonCohort
omega3FattyAcids
percecntConfidenceIntervals
Depletion
appearance
caseRecords
found
atypia
eConcentration
sensor
syndromes
subsequentRadiomics
Survival
evaluation
theory-basedIntervention
TP53
age-matchedSystematicRandom-samplingMethod
capacitance
expectedInverseCorrelation
comprehensiveSearch
itsExpressionLevel
summaryHazardRatios
severalPatients
DAU
Referrals
NSAIDs
promoterMethylationStatus
total
antigenIdentification
tumors
sialicAcidExpression
therapeuticSequencing
methods
tumorNippleDistance
We
MicroRNAs
differentialDiagnoses
interference
ultrasound-guidedDiffuseOpticalTomography
scope
breastCancerStudies
mostStigmatization
enforcedExpression
treatment
percecnt
oneSpecificSubtype
characteristics
dcisDiagnosis
estrogenicExposure
capabilities
age-basedScreeningPrograms
usExaminations
megakaryocytes
dataAnalytics
uniqueEsr1Mutations
mutationEvents
firstOrganisedRound
fastRate
need
treatmentRegimens
DSCAM-AS1
luminalB-likePatients
death
15Percecnt
interplay
novelPowerfulTechnique
collectedSignatures
micrometastasis
sentinelNodeBiopsy
benchmarkMethod
accuracyScores
palliativeChemotherapy
participants
186Pathology-provenS
significantDifference
yoga
FXYD3
greatProgress
associations
hypomethylation
detectionMethod
ongoingTrials
preclinicallyTams
knowledge
Delays
ourResults
controls
functionalAssessments
ruralCancerHospital
lesion
women'sPersonalGoals
elevatedLesion
carrier
foodRecommendations
RANKL
chinesePublic
blood
importantPotential
positiveChanges
means
psychologicalAspects
primaryCareProvider
ddtSprays
cell
results
youngMen
fine-needleAspirationCytology
complication
rate
biologicalSubtypes
non-standardPromptTreatments
ruralSetting
patients
resultsDiagnosed
group1
cancerCareCenter
DDT
invasiveLobularHistology
differentProtocols
agreement
282Patients
exercise
miR-511
surgicalImplantationReconstruction
long-termUse
77Patients
specificEralpha-targetedProbe
antibodyPanel
radiationTherapy
rnaOligonucleotides
sequencing
correlation
performance
analysis
osteopontin-750Accumulation
mastectomy
bioimpedanceAnalysis
cancer
osteopontin-basedProbe
mabaSurgery
inAssay
manyBreastCancerPatients
betterUnderstanding
20
relationship
proteinKinase
hormone-dependentPositiveBreastCancer
odds
0.84
newTreatmentRegimens
noninvasiveImaging
emphasis
esr1-activatingMutations
Patients
doses
outcome
51Patients
antibody-anchoredMagneticBeads
lipidProfiles
responsibleMechanisms
subtype
Kazakhstan
SUVmax
methodsDesign
focus
PCDH10
11HereditaryBreastCancerGenes
antibodies
probe
cross-sectionalStudy
Information
molecularBasis
Access
improvedCancerTreatment
r
Resurgery
infiltrationSimilar
overexpression
icgFluorescenceMethod
differentials
heterogeneity
ELISA
stereotacticWire-guidedBiopsy
postAssessment
andfemales
paraneoplasticAntibodyPanel
careProvider
netvizzApplication
tanUsage
bestAvailableEvidence
eventualKnowledge
murineMonoclonalAntibodies
binaryLogisticRegressionModels
manyFeatures
They
metastasis
coding
resonanceImaging
PR
commonComplaint
equivalentPerformance
highIndex
ctcCounts
olderWomen
TAM
women
535941Survivors
clearcellPlatform
localTherapy
specificFoodRecommendations
GTPase
feasibleCtcIsolationTechniques
postmenopausalPatient
disease
Protocadherin-10
biomarker
breastCancerCases
multiresolutionResult
membraneTypeMr
methylationStatus
contribution
contraceptionUse
weight
locoregionalRadiotherapy
vap-1StainingResults
similarPfs
imagingIndexes
transcriptionFactorForkheadBoxC1
healthCenters
multigenePanels-with
betterOs
Radiotherapy
2-groupRandomizedControlTrial
Using
summary
classifiers
membraneTypeMannoseReceptor
neoadjuvantChemotherapyGroups
identification
cancerControlPlanning
heartFailure
chineseExpertGroup
twoImagingIndexes
effectiveness
molecularAnalyses
information

objectiveResponseRate
typicalWoman
subset
precision
Mutations
estrogens
goodTolerabilitytheApatinib
description
troponins
Nek6
currentFollow-up
HR
mutations
12331Users
otherData
Patients
CLB-Pt-CLB
prognosis
metastases
case
short-termStrategy
tomography
mainChallenge
chestCtScans
collapsing
miRNAs
cross-validation
finalMultipleRegressionModel
408
cpgIslands
variants
furtherUnderstanding
decreasedExpression
differentLong-termSurvival
concentrations
breastCancerControl
lowLevel
excision
carbohydrateRestriction
its
macrophages
genes
fisherDiscriminantAnalysis
606Percecnt
neoadjuvantChemotherapy
interpretation
sentinelLymphNodeBiopsy
pharmacokineticParameters
screening
extensiveExploration
Overexpression
Investigation
tertiarySexualHealthCenters
components
mammographicBreastCancerScreening
mastectomies
we
massMedia
dual-phaseContrast
This
anti-ronMonoclonalAntibodyZt/g4-drugMonomethylAuristatinEConjugate
25CaseReports
smallMoleculeInhibitors
leucocytes
xenograftMice
guidedImagery
late-stageCancerDiagnosis
risks
occurring
surgicalOutcome
microscopicExamination
fxyd3Amplification
synthesisMethods
proposedCovariance-basedSpdMatrices
contrast
Anthracyclines
HT
nuclearAtypia
Data
pharmacokineticParameters
tissues
menopausalHormoneTherapy
propensityScoreMatchingAnalysis
simulatedInnerBreastTissue
little
years
nondestructiveTests
Individuals
improvedUnderstanding
personalDecision-making
AYAs
p
article
22Patients
Factors
findings
dictionaryLearning
secondLargestHmo
carbonDioxideLaserTechnology
epidemiologicalFeatures
ourResults
coxProportionalHazardRegressionModels
history
comparisons
sentinelLymphNode
cancerRiskPerception
risk-stratifiedScreeningStrategy
0-5Years
dscam-as1Expression
annexinVStaining
inclusion
specificGroups
frequentMutations
survivalRate
humanEpidermalGrowthFactorReceptor2ReceptorStatus
purpose
hypomethylationSites
survival
highCoverage
rural-basedTertiaryCancerCareCenter
cylindricalGeometries
knockdown
suutaneousBreastTumor
breastCancerDiagnosis
archivedFormalin-fixedParaffin-embeddedTissue
brainMetastases
lungCancer
materialDetection
shapes
Findings
SNVs
random-samplingMethod
oestrogenReceptorAlpha
issues
imaging
mriImaging
greatPromise
clinicalOutcomesDiffer
meanTime
cytology
program
recentDanishCohortStudy
mutationRatio
imagingTechnique
authors
allBreastCancerPatients
deep-CNN
sensitiveNano-genosensor
level
existence
impact
incidence
pathogenicVariants
Immunohistochemistry
breastConservation
obstetricians
chorea
magneticResonanceImaging
opticalAbsorptions
myeloperoxidase
similarTowaveletFilter
individuals
symptomaticWomen
they
propagation-basedPhase-contrast
fastingBlood
tumour
intracellularLevel
rareClinicalPresentations
sparseCoding
gonadotropin
theirParaffin-embeddedTissues
secondaryLymphedema
cell-killingEffect
77
volume
mechanisms
discovery
mir-511Overexpression
Cell
Mammography
endocrineResistance
causes
solubleSt-2Level
zero-inflatedPoissonRegression
factor-1Scores
label-freeDetection
recentStudies
advancedStage
areas
learning
effects
Disease
anticipatedOutcome
commonAdultCancers
symptomaticHeartFailure
actualIncidence
basis
contraceptiveUse
panel
nek6Expression
parameters
otherSignificantConcerns
40
conditions
medianDiagnosisAge
excellentPerformance
pH
conjugatedEquineEstrogen
biopsy
ductalCarcinoma
tenfoldCross-validationMatthew
framework
diagnosed
portugueseInstitute
patient'sMedicalHistory
MRI
medianProgression-freeSurvival
nanocarrier
technique
differentStudies
five
mortalityRates
Spouses
decrease
itsRole
highExpression
mass
hugeVolumes
prevention
non-coverage
otherDietaryRecommendations
Metastasis
stageI/iiaCases
coverage
pearson'sR
femalePatients
She
Screening
tumor-associatedMacrophages
trastuzumab/pertuzumab/taxane
42Patients
insight
186S
prospectiveNestedCase-controlStudy
anthracyclineChemotherapyAgents
emergingTechnology
hormonalContraceptionUse
preoperativeUnderstanding
P
axillaryLymphNode
threeDifferentClusters
adjustedProportion
TBR
CNVs
contrastAgents
mainObjective
RNAs
cohortStudy
nano-genosensor
recommendations
breastCancerRisk
relapse
considerableNumber
recurrence-free-survival
12-15Percecnt
stromalExpression
RDD
nodalMegakaryocytes
largeBreastCancerTissueMicroarray
bilateralMastectomies
regressionModel
bio-metal-organicFrameworkCoated
historyPhysicalExamFindings
theirTissues
AMD3100
Identification
geometries
99Percecnt
Comparisons
newerDrugDeliveryStrategies
similarSeriousAdverseEvents
signature
morphologicalDifferentials
lymphedemaseventyPatients
highCorrelation
microRNA-22
patient'sTumorBurden
estrogenReceptor-alpha
search
importantRole
Results
phenotypeExpression
conclusionsWomen
SVM-BRC
extramedullaryHaematopoiesis
undifferentiatedNeoplasticCells
magneticResonanceImaging
geneticChanges
woman
HADS
10Mg/kg
Increase
Utilization
survivalData
pdgfs/pdgfrsAxis
score
CTC
specificSubtype
analyses
review
experience
NAC
deepLearning
clinico-pathologicalRiskFactors
breastImagingModality
intelligentTechniques
undergoing
pathway
aberrances
lowCtnLevels
increasingNumber
kaplan-meierCurves
sentinelLymphNodeBiopsy
traditionalPredictors
NLR
data
groups
significantAdvances
surgicalExcision
importance
Women
multidisciplinaryAssessment
84Patients
she
longerPfs
trastuzumab
bpeLevels
inhibited
expression
immunohistochemicalAnalysis
increase
double-maintenanceTherapy
147Patients
switch
highestSe
aptamerMf3
Associations
picture
understanding
proportion
options
adhesionProtein-1
boneDensity
stage
role
commonCause
nirFluorescenceImagingSystem
immediateUnmetNeed
hypothesis
tissueDiagnosis
suchStandardization
radiotherapy
commonCancerTypes
their
determining
pattern
performed
parpInhibitors
nsaidExposure
pi3k/aktSignaling
factors
physician
imageQuality
observationalStudies
itsExpression
backgroundTrastuzumab
smallerMyeloperoxidase
alternativeOption
Mechanisms
mainMeasures
non-sentinelLymphNode
Univariate
smallPopulation
maleBreastCancer
54BreastCancerPatients
Pearson
ourTheoreticalAnalysis
fiveYearRfsrate
lobularCarcinoma
complexConsulting
rnaSequenceAnalysis
distinctiveGeneticModifications
st-2Level
22Deaths
surgery
it
interview
highSensitivity
ageGroups
peripheralBloodSamples
staining
dynamicContrast
chemotherapyRegimens
stagingSystems
analyzing
mtorInhibitorEverolimus
exposure
decreasedBpe
ssdnaAptamerMf3
mastectomizedWomen
breastCancer
evidence
result
molecularRegulatoryNetworks
evidence-basedRecommendations
massiveCircrnas
towaveletFilter
mostWomen
mammograms
primaryTumours
convolutionalNeuralNetworks
133BreastCancerCases
large-scaleStudies
monteCarloFeatureSelection-basedFeatureSelection-basedComputationalMethod
ourBreastCancerPatients
2921Posts
coxHazardRegressionAnalysis
Co-existence
obstetrician
longerPeriods
tumor-to-backgroundRatio
irregularHyperintenseLesion
hyperglycemia
finding
firstTime
research
multipleGeneticAberrances
of121Patients
aim
combinedAnalysis
involvement
Biomarkers
techniques
mostPretermBirth
triple-negativeBreastCancer
carcinoma
late-stage
clinicalRecords
biocharacter
most
Steps
population
agonistic/antagonisticBiocharacter
usStandardization
alexnetModels
accuracy
recentEpigenomeStudies
cytologicalExamination
diagnosticRole
multivariateCoxProportionalHazardRegressionAnalysis
diagnosticUncertainty
decreases
ca15-3Detection
predictors
surgicalOutcomes
shorterRadiotherapyRegimens
nsaidUsers
rs5743810ProAllele
levels
quadrantectomy
single-nucleotideVariants
triple-negativeBreastCancer
numerousGene-expression-basedPrognosticSignatures
directEffects
regressionModels
fibroblastsAdjacent
ratio
prognosticValue
signatures
follow-up
traumaticBreastNeuromas
transferLearning
subtype-specificSignature
concerns
intraoperativeScrapeCytology
additionalInformation
increases
treatments
baselineSolubleSt-2Level
DESI-MSI
70-year-oldWoman
undergone
invasiveBreastCarcinoma
12404Patients
China
lungChanges
speed
induction
smallProportion
australianSynchrotron
-916
development
PALB2
theory
twoChlorambucilPlatinum
futureInterventions
ccsCoverage
geneExpressionLevel
combinedPanel
internationalGuidelines
Mammographic
majority
accumulatingResults
Cholecystectomy
BRCAs
microrna-22ExpressionLevels
suchSymptoms
simulatedBreastCancer
treatmentProcesses
kinds
paraneoplasticNeurologicSyndromes
higher-qualityImaging
hazardRates
suutaneousEcchymosis
cutoff
mastectomiedPatients
mStage
transport
shallowCnn
bloodSamples
humanChorionicGonadotropin
highestRisk
SOX9
incidenceRates
breastScreening
molecularChanges
Follow-up
definedSubtype
networks
textureAnalysis
main
image
significantHigherRisk
breastCancerScreening
CTCs
breast
furtherResearch
MethyLight
preoperativeDiagnosis
novelNavigationSurgery
properties
asymptomaticWomen
baselineSt-2Level
management
100Patients
furtherTissue
breastCancerGenetics
tolerabilitytheApatinib
therapies
experiences
westernBlotAnalyses
sustainedStableDisease
Obesity
activities
metastaticDisease
quantitativeParameters
statisticalClassifiers
tumorUptake
limitedLiterature
survivalRates
studies
breastCancerDetectionMethod
clb-pt-clbProdrug
LVI
breastCancer
Ki67
VEGF-D
Validation
syndrome
higherProportion
microfluidicChips
screeningTools
spouse
survivalDistributions
outcomes
occurrence
secondTumor
oneMutation
currentAnalysis
diagnoses
OP
estrogen
osAdvantage
clinicalCharacteristics
mixedMethodsDesign
characterization
omegaFattyAcids
third
STAT1
eighthEdition
time
complaint
elderlyPatients
ORR
mechanism
biomarkers
FOXC1
criticalScientificBase
selectedPatients
breastCancer-specific10-yearSurvival
overallMedianSurvival
diseases
literature
usefulness
navigationSurgery
longNoncodingRnas
wordCloud
lowerCumulativeHazardRates
algorithm
racialDisparity
macrophage-targetedTreatmentStrategies
currentUtilizedHistopathologicBiomarkers
SP
nsaidsExposure
correlationCoefficient
multidimensionalScaling
Diseases
Non-linearity
Baicalin
breastCancerRelapse
diagnosticEvaluation
133Controls
value
ddtExposure
unbiasedRnaSequenceAnalysis
controlTrial
ourLiteratureReview
presence
glut1Expression
two-yearStudy
intensive
separateClassificationModels
quality
newSpecificMarkers
barcodeMode
risk
theirLong-termSurvival
clinicians
autoimmuneDiseases
model
multivariate
RRM2
solicitations
100000Person-years
Cells
scffbxo22-mediatedKdm4bDegradation
lowClassificationAccuracies
pD1542yMissenseMutation
number
Recurrences
breastNeuromas
interval
mainContribution
earlyBreastCancerDetectionSystems
currentMeans
therapy
haveCenterstage
esr1Alterations
1000Patients
PFS
proposedMethod
identified
clinicalPicture
furtherStudies
blackWomen
colonyFormation
differentDetectionRates
hundreds
massProduction
aspects
mab1e3
diagnosis
Researchers
appropriateInterpretation
rareTumor
detection
reverseTranscription-quantitativePolymeraseChainReaction
coxHazardRegressionModels
post-nacBpeLevels
902Percecnt
screeningPrograms
omission
subjectiveRisk
quantitativeRealTimeFluorescencePolymeraseChainReaction
4248BreastCancerPatients
targetedTherapies
conventionalX-rayMammography
DDTs
optimalCutoffValues
treatmentOutcomePrediction
nanoplatform
overallSurvival
protocols
circRNAs
recurrentWords
effect
AION
mostPatients
detectionofBreastCancer
figures
age
complexSurgeries
multimodalTherapy
tissueBiopsy
428BreastCancerPatients
medianAge
DCIS
firstSteps
erImmunohistochemistry
changes
TAAs
cTn
Cryopreservation
oxidationPeakCurrent
cancerStemCellHypothesis
optimalCut-offValue
tissue
160Patients
study'sObjectives
moreIntensiveFollow-up
Probes
treatmentStrategies
neuroma
imageSegmentation
measurements
comparisons10-yearSurvival
sixCirculatingMirnas
relatedTranscriptionFactorSox9
chemotherapyRecommendations
otherAgeGroups
CEDM
twentyUniqueEsr1Mutations
delay
obtainedFeatures
erEvaluation
stableDrug-carrierBinding
intervention
spdMatrices
cardiacTroponins
chemotherapy
mammographicImages
65Patients
proteinExpression
Use
conventionalTreatmentProcesses
state-of-the-artAlgorithms
morcFamilyCw-typeZincFinger4Overexpression
700
proposedAlgorithm
experts
practitionersKnowledgeable
12331Non-nsaidUsers
study
outliers
occultBreastTumors
increasedRonExpression
target
femalePatient
OR
ecchymosis
chemotherapyHormonalTreatment
craniotomy
the
35-64Years
expressionLevels
post-NAC
VAP-1
breastCancerPatients
invasiveDuctalCarcinoma
responseRate
nippleInvolvement
localRecurrence
CGI
remarkableImprovements
476Years
analysisMayAid
rarePresentations
all
65-year-oldFemale
necessity
56Patients
sharedSnvs
aromataseInhibitor-inducedBoneLoss
nondestructiveTesting
coverageRates
medianInterval
metastaticDisease
care
riskFactors
microfluidicPlatform
poorerOutcome
detailedRoles
strongContrast
surfaceMorphology
sParticipants
objective
inhibition
assay
vap-1Expression
futureClinicalStudies
patient
priorMedicalHistory
metabricTrainingSet
TAMs
variousMethods
morphologicParameters
lymphocytes
esr1SomaticAlterations
mortality
variousNon-pharmacologicalAdjuvantTherapies
drugDeliveryStrategies
Cases
respondents
Zt/g4-MMAE
tumor
overallMediumSecondTumor-freeTime
volumes
msotImaging
fibroblasts
challenge
obesity
multiplexAssay
significance
epigeneticAberrations
screeningStrategy
sentinelNodes
splenicLymphocytes
Management
furtherStudies
features
lisbonRegion
breastCancerPatients
differentiation
samples
presentations
significantIncrease
extremeLearningMachineClassification
chemotherapyGroups
manyComputerVisionApplications
DCR
Tumours
dnaMethylation
dissection
drugBinding
microarrayAnalysis
therapeuticTarget
examination
breastMetastases
histopathologicalreports
cases
20BreastCancerPatients
adjuvantEndocrineHormonalTherapy
1
38-year-oldFemale
8155Patients
overview
signalIntensity
use
denosumabInjection
ET
urgentCytology
plasmaLevels
advancedBreastCancer
increasedRisk
cancerFibroblasts
Applications
1444Women
eralphaTranscription
factorAnalysis
CellLines
scan
7581StageI/iiaCases
medicalStatus
firstDiagnosis
publicHealthCareSystem
SD-CNN
medianTime
subtypes
miR-204-5p
ESR1
radiomics
rs5743810
commonCancer
cytohistologicalComparisons
tools
z-test
available
method
slnBiopsy
recentDevelopments
malePatients
cancerResearch
numberVariants
targetedTherapies
linerRegressionAnalysis
prognosticStagingSystems
pleuralMetastasis
ivimParameters
conservativeTreatment
3ClinicopathologicalFactors
markers
goal
12SampledWomen
additionalAnalyses
breastSurvival
furtherDevelopment
lifestyleModification
water
multidisciplinaryCare
mPatients
comparison
recognizingMethylationStatus
fewStudies
progressionDisease
multipleSolicitations
successfulQuantification
morc4Silencing
10-foldCross-validation
roles
tumours
Acupuncture
association
standard
selectedStandardTreatments
alternativeContrast-enhancedScreeningTools
miR-34s
almatyCity
TRPV1
chlorambucilPlatinum
reporterAssays
esr1Mutations
dual-luciferaseReporterAssays
tumorSuppressorFunction
prospectiveStudies
axillarySurgery
occurringCancers
prediction
hospitalCohort
-25-diphenyltetrazoliumBromideAssay
localizedDescription
pathologists'Awareness
keyHypomethylationSites
ourAim
vap-1NegativeStaining
healthcareUtilization
alternativeMeans
coxModel
advancedBreastCancerBearingMutations
Risk
three-yearSurvivalRates
breastCancer
49Patients
ctcIsolationTechniques
Computer
adherence
wavelengthConsistencyIndex
Residents
matchedHealthyTissues
adPatients
parameterUncertainty
axillaryDissection
9398
substantialImprovements
cancerAssociatedFibroblasts
receptorActivator
luciferaseReporterAssay
heterogeneousDisease
sevenWomen
material
strategy
cutoffValues
guidelines
improvedDetection
It
decreasedRisk
nippleAreolaComplexInvolvement
patients'Prognosis
polycysticOvarySyndrome
appropriateSequencing
neoadjuvantTreatment
fluorescenceImagingExVivo
differentPrognosis
robustSynthesisMethods
CNN
youngMalePatients
rnaKnockdown
481Women
directTargetGene
totalOf121Patients
traumaticNeuroma
BPE
952PercecntOfthePostmenopausalWomen
histologicalExamination
relapseRates
jak-statPathway
Therapies
clinicalDepression
Belgium
caloricRestriction
circulatingSolubleRankl
advances
pathologicalSpecimen
enhancerRegions
virtualReality
capillaries
bromideAssay
highGlut1Expression
novelty
otherInotherTertiaryCentres
ourPatient
muchFocus
mirnaExpressionProfiles
positiveTreatment
poorerPrognosis
paTreatment
breastCancerMetastasis
treatmentProtocols
tumorSizethePositivity
those
accurateMethod
familySupport
first-lineTreatment
availableContrastAgents
circulatingTumorCells
support
Familiarity
tangshanPeople
ERBB2
pathologicalResults
Estrogen
networkOutput
twoScales
cells
repair
selectiveBinding
Targeting
trend
PM
similarExperimentalParameters
binding
mostNondestructiveTests
histoneModifications
autoantibodies
suutaneousLymphaticChannels
RON
manyPatients
caDetection
breastCancerScreening
monteCarloFeatureFeatureMethod
resistance
postOperativeAssessment
targetingFxyd3-mediatedPathway
radiomicsScore
a
newBilateralIntrapulmonaryNodules
vascularAdhesionProtein-1
estrogenReceptor
inflammatoryTumour
stigmatization
platform
three-lncrnaSignature
cancerSusceptibilityGenes
Wilm
flankingCgi
fisherAnalysis
baicalin
Transcripts
multi-stimuli-responsiveTheranosticNanoplatform
activity
comprehensiveResearchData
higherResolution
segmentationAlgorithm
counseling
hybridCultures
novelMethod
clinicalBreastExamination
measures